WO2002026754A3 - Oligonukleotide, diese enthaltende mittel und deren verwendung - Google Patents

Oligonukleotide, diese enthaltende mittel und deren verwendung Download PDF

Info

Publication number
WO2002026754A3
WO2002026754A3 PCT/EP2001/011258 EP0111258W WO0226754A3 WO 2002026754 A3 WO2002026754 A3 WO 2002026754A3 EP 0111258 W EP0111258 W EP 0111258W WO 0226754 A3 WO0226754 A3 WO 0226754A3
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotides
agents containing
pancreatic tumors
proliferation
inhibiting
Prior art date
Application number
PCT/EP2001/011258
Other languages
English (en)
French (fr)
Other versions
WO2002026754A9 (de
WO2002026754A2 (de
Inventor
Ernst Bayer
Thomas Ketterer
Holger Kalthoff
Hendrik Ungefroren
Michael Gerster
Alexander Fiedler
Original Assignee
Ernst Bayer
Thomas Ketterer
Holger Kalthoff
Hendrik Ungefroren
Michael Gerster
Alexander Fiedler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ernst Bayer, Thomas Ketterer, Holger Kalthoff, Hendrik Ungefroren, Michael Gerster, Alexander Fiedler filed Critical Ernst Bayer
Priority to EP01985701A priority Critical patent/EP1326878A2/de
Priority to AU2002215911A priority patent/AU2002215911A1/en
Priority to US10/381,869 priority patent/US7608705B2/en
Publication of WO2002026754A2 publication Critical patent/WO2002026754A2/de
Publication of WO2002026754A3 publication Critical patent/WO2002026754A3/de
Publication of WO2002026754A9 publication Critical patent/WO2002026754A9/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/18—Type of nucleic acid acting by a non-sequence specific mechanism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft bestimmte Oligonukleotide, pharmazeutische Mittel, die diese Oligonukleotide enthalten, und deren therapeutische Verwendung. Die Oligonukleotide sind insbesondere in der Lage, die Proliferation von Prankreastumoren zu hemmen. Damit besitzen diese Oligonukleotide ein therapeutisches Potential zur Behandlung von Pankreastumoren. Es kann sich im weitesten Sinne um eine Antisense-Therapie handeln.
PCT/EP2001/011258 2000-09-28 2001-09-28 Oligonukleotide, diese enthaltende mittel und deren verwendung WO2002026754A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP01985701A EP1326878A2 (de) 2000-09-28 2001-09-28 Oligonukleotide, diese enthaltende mittel und deren verwendung
AU2002215911A AU2002215911A1 (en) 2000-09-28 2001-09-28 Oligonucleotides, agents containing these oligonucleotides, and the use thereof
US10/381,869 US7608705B2 (en) 2000-09-28 2001-09-28 Oligonucleotides, agents containing these oligonucleotides, and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10048091A DE10048091A1 (de) 2000-09-28 2000-09-28 Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
DE10048091.8 2000-09-28

Publications (3)

Publication Number Publication Date
WO2002026754A2 WO2002026754A2 (de) 2002-04-04
WO2002026754A3 true WO2002026754A3 (de) 2002-12-05
WO2002026754A9 WO2002026754A9 (de) 2003-05-15

Family

ID=7657971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/011258 WO2002026754A2 (de) 2000-09-28 2001-09-28 Oligonukleotide, diese enthaltende mittel und deren verwendung

Country Status (5)

Country Link
US (1) US7608705B2 (de)
EP (1) EP1326878A2 (de)
AU (1) AU2002215911A1 (de)
DE (1) DE10048091A1 (de)
WO (1) WO2002026754A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10048091A1 (de) 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor
DE10346721A1 (de) * 2003-10-08 2005-05-04 Holger Kalthoff Oligonukleotide, diese enthaltende Mittel und deren Verwendung

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876335A (en) * 1986-06-30 1989-10-24 Wakunaga Seiyaku Kabushiki Kaisha Poly-labelled oligonucleotide derivative
WO1993007883A1 (en) * 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6013788A (en) * 1999-04-09 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad3 expression
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US6037142A (en) * 1999-02-23 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of SMAD2 expression
US6080546A (en) * 1999-07-23 2000-06-27 Isis Pharmaceuticals Inc. Antisense modulation of MEKK5 expression
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6103498A (en) * 1996-04-12 2000-08-15 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
US6107091A (en) * 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US6124272A (en) * 1999-04-09 2000-09-26 Isis Pharmaceutical Inc. Antisense modulation of PDK-1 expression
WO2001036625A2 (en) * 1999-11-18 2001-05-25 Genesense Technologies, Inc. ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US5245022A (en) * 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5552390A (en) * 1993-12-09 1996-09-03 The Board Of Regents Of The University Of Nebraska Phosphorothioate inhibitors of metastatic breast cancer
EP0856579A1 (de) * 1997-01-31 1998-08-05 BIOGNOSTIK GESELLSCHAFT FÜR BIOMOLEKULARE DIAGNOSTIK mbH Ein Verfahren zur Zubereitung von Antisense Oligonukleotiden
DE69932346T2 (de) * 1998-10-26 2007-07-05 Avi Biopharma, Inc., Portland Auf Morpholin basierendes p53-Antisense- Oligonucleotid und dessen Verwendungen
US20040241651A1 (en) * 2000-04-07 2004-12-02 Alexander Olek Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
DE10048091A1 (de) 2000-09-28 2002-04-25 Ernst Bayer Anwendung chemisch modifizierter Oligodesoxyribonukleotide zur Unterdrückung der Proliferation von humanem Pankreastumor

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4876335A (en) * 1986-06-30 1989-10-24 Wakunaga Seiyaku Kabushiki Kaisha Poly-labelled oligonucleotide derivative
WO1993007883A1 (en) * 1991-10-24 1993-04-29 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6033909A (en) * 1992-01-22 2000-03-07 Hoechst Aktiengesellschaft Oligonucleotide analogs, their preparation and use
US6103498A (en) * 1996-04-12 2000-08-15 American National Red Cross Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof
US6107091A (en) * 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US6037142A (en) * 1999-02-23 2000-03-14 Isis Pharmaceuticals Inc. Antisense inhibition of SMAD2 expression
US6013788A (en) * 1999-04-09 2000-01-11 Isis Pharmaceuticals Inc. Antisense modulation of Smad3 expression
US6124272A (en) * 1999-04-09 2000-09-26 Isis Pharmaceutical Inc. Antisense modulation of PDK-1 expression
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6080546A (en) * 1999-07-23 2000-06-27 Isis Pharmaceuticals Inc. Antisense modulation of MEKK5 expression
WO2001036625A2 (en) * 1999-11-18 2001-05-25 Genesense Technologies, Inc. ANTISENSE OLIGONUCLEOTIDE SEQUENCES DERIVED FROM groEL AND groES AS INHIBITORS MICROORGANISMS

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BAYER E ET AL: "SYNTHESIS OF 3'-PEG-MODIFIED OLIGONUCLEOTIDES ON PS-PEG TENTACLE POLYMERS", ZEITSCHRIFT FUR NATURFORSCHUNG, TEIL B: ANORGANISCHE CHEMIE, ORGANISCHE CHEMIE, VERLAG DER ZEITSCHRIFT FUR NATURFORSCHUNG. TUBINGEN, DE, vol. 4, no. 50, 1995, pages 671 - 676, XP001063225, ISSN: 0932-0776 *
FEARON, KAREN L. ET AL: "Investigation of the 'n-1' impurity in phosphorothioate oligodeoxynucleotides synthesized by the solid-phase.beta.-cyanoethyl phosphoramidite method using stepwise sulfurization", NUCLEIC ACIDS RES., vol. 23, no. 14, 1995, pages 2754 - 2761, XP001063116 *
HAHN S A ET AL: "RECENT DISCOVERIES IN CANCER GENETICS OF EXOCRINE PANCREATIC NEOPLASIA", DIGESTION, BASEL, CH, vol. 5, no. 59, August 1998 (1998-08-01), pages 493 - 501, XP001063030, ISSN: 0012-2823 *
HIROTA Y ET AL: "P53 ANTISENSE OLIGONUCLEOTIDE INHIBITS GROWTH OF HUMAN COLON TUMOR AND NORMAL CELL LINES", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, vol. 7, no. 87, July 1996 (1996-07-01), pages 735 - 742, XP001062844, ISSN: 0910-5050 *
LEBEDEVA I ET AL: "Cellular delivery of antisense oligonucleotides", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, NL, vol. 50, no. 1, 3 July 2000 (2000-07-03), pages 101 - 119, XP004257182, ISSN: 0939-6411 *
MAIER M, BLEICHER K., KALTHOFF H., BAYER E: "Enzymatic degradation of various antisense oligonucleotides : monitoring and fragment identification by mecc and es-ms", BIOMEDICAL PEPTIDES, PROTEINS AND NUCLEIC ACIDS, vol. 1, 1995, pages 235 - 242, XP001057392 *
MANOHARAN M ET AL: "OLIGONUCLEOTIDE CONJUGATES: ALTERATION OF THE PHARMACOKINETIC PROPERTIES OF ANTISENSE AGENTS", NUCLEOSIDES & NUCLEOTIDES, MARCEL DEKKER, INC, US, vol. 14, no. 3/5, 1995, pages 969 - 973, XP002913881, ISSN: 0732-8311 *

Also Published As

Publication number Publication date
WO2002026754A9 (de) 2003-05-15
DE10048091A1 (de) 2002-04-25
US7608705B2 (en) 2009-10-27
US20050019761A1 (en) 2005-01-27
AU2002215911A1 (en) 2002-04-08
WO2002026754A2 (de) 2002-04-04
EP1326878A2 (de) 2003-07-16

Similar Documents

Publication Publication Date Title
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
EP1140840A4 (de) -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
HK1155944A1 (en) W-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IL196301A0 (en) Medicament for the treatment of hapatitis c
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
NO20031521D0 (no) Assosiasjon av CB1-reseptorantagonist og et sibutramin, farmasöytiske preparater inneholdende denne samt dens anvendelse for behandling avfedme
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
HUP0202319A2 (en) Use of mek inhibitors for the preparation of pharmaceutical compositions treating chronic pain
ZA200200738B (en) Use of monoamine oxidase inhibitors for the manufacture of drugs intended for the treatment of obesity.
EP1446012A4 (de) Bakteriolytische kombinationstherapie für die behandlung von tumoren
YU13603A (sh) Postupci tretiranja poremećaja povenzanih sa bcl-2 primenom bcl-2 antisens oligomera
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
HK1048337A1 (en) Oligonucleotides for inhibiting the expression of human eg5.
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
MXPA03007903A (es) Sistema terapeutico transdermico altamente flexible con nicotina como ingrediente activo.
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
WO2000032765A3 (en) Ribozyme therapy for the treatment and/or prevention of restenosis
HK1048441A1 (en) Drug for treating fractures
WO2002026754A3 (de) Oligonukleotide, diese enthaltende mittel und deren verwendung
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.
WO2002028874A3 (en) Tumor proliferation inhibitors
PL355285A1 (en) Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance
AU5802200A (en) Agent for gene therapy and for the prevention of metastases, as well as for the gene therapy of tumors
AU2002325345A1 (en) Use of inhibitors of expression or activity of p8/com1 for treating tumors.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001985701

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001985701

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10381869

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001985701

Country of ref document: EP